Founders
Dr. Guang Yang
Chairman and Chief Scientific Officer (CSO)
Dr. Yang had been working in several multinational pharmaceutical companies such as Novartis, Roche, and Johnson & Johnson. Prior to founding Aubrak Therapeutics, he was the R&D Director of Johnson & Johnson at the China R&D Center. He has more than 20 years of leadership experience in drug discovery and development. Throughout his tenure in these companies, he had successfully led and participated in quite a few new drug discovery projects.
Dr. Yang obtained his Ph.D. degree from the Hebrew University of Jerusalem, Israel, and conducted his postdoctoral research at the Howard Hughes Medical Institute, University of Southern California, USA.
Dr. Jeff Zhang
Chief Executive Officer (CEO)
Dr. Zhang has nearly 30 years of experience in innovative drug development and management. Prior to founding Aubrak Therapeutics, he served as the director of Novartis Institutes of Biomedical Research and the CSO of Youngene Therapeutics. He has previously worked in many top multinational pharmaceutical companies such as Pfizer and GlaxoSmithKline. He has rich experience in novel drug research and development, has published more than 50 research papers in peer-reviewed journals, and holds numerous international patents.
Dr. Zhang has led and participated in dozens of innovative drug projects ranging from early-stage new drug discovery to translational medicine and clinical stage, of which 8 drugs are now on the market (Celebrex, Bextra, Dynastat, Inspra, Tykerb, Navelbine, IncruseEllipta, Scemblix).
Dr. Zhang obtained his Ph.D.degree in organic chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and a bachelor's degree in chemistry from Hangzhou University (now Zhejiang University). He conducted his postdoctoral research in clinical pharmacology at Vanderbilt University, USA.
Dr. ZHENGMING DU
Chief Technology Officer(CTO)
Dr. Zhengming Du possesses over 30 years of the pharmaceutical industry and academic experience including early drug discovery, late drug development, registration, and commercialization. He also has extensive experience in management and has been leading global teams to succeed in multiple IND and NDA approvals. Before being co-founder and CTO of Aubrak Therapeutics, Dr. Du used to work as a senior vice president at BeiGene, director at Roche (China), deputy general manager of Huahai Pharmaceuticals, and leading chemist in Novartis USA.
Dr. Du holds a Ph.D. from Clark University in the United States, and a bachelor's degree in chemistry from Nanjing University. He has published more than 30 peer-reviewed scientific papers and authorized more than 20 international and domestic patents. He has won many awards including the Novartis Pharmaceuticals Global Resource Efficiency Award, Roche Innovation Project Outstanding Contribution Award, Chinese Chemical Society Outstanding Young Chemist Award, Jiangsu Science and Technology Progress Award, Leader of Major Scientific and Technological Innovation Projects in Jiangsu Province, Leader of Jiangsu Double Entrepreneurship Team and National Talent Experts.
Pre-A轮重要投资机构
南京复星通睿基金是国际化医药健康产业集团复星医药（600196.SH,02196.HK）旗下的创业投资基金，基金在南京江北科投集团的支持下于2021年7月设立，规模5亿元人民币，专注投资于中早期生物医药企业，由通德资本担任基金管理人。通德资本是一家专注于投资生物医药的VC机构，主要投资创新药和创新生物技术等领域，以早期和成长期项目为主。团队拥有深厚的产业背景、丰富的产业和金融资源、以及孵化和助力被投公司成为行业领导者的成功经验。
南京其瑞佑康基金成立于2018年，是由南京江北科投集团出资设立、规模7亿人民币的创业投资基金，由恩然创投担任基金管理人，是一只专注于生物技术、医疗医药的科技创新股权投资基金。基金设立以来深耕江北新区，已累计投资医疗科技企业10多家，包括药捷安康、维立志博、征祥医药等。恩然创投成立于2015年，专注于生命科学、健康医疗、创新，秉承主动投资理念，在全球生物医药和医疗健康产业链战略性地对产业中的革命性新技术、新产品进行投资布局。
锐合资本由资深的产业和金融界人士于2010年创设，专注信息技术、医药健康和文化创意领域的股权投资，目前管理资金近30亿元，近年来A股上市案例包括泛微网络、美诺华、保隆科技、绿色动力、泰坦科技等。医药健康方面，依托来自医药界的专业团队，锐合资本已领导投资了美诺华、阿诺医药、华先医药、智核生物、美克医学等优秀企业。
成都苑东生物制药股份有限公司是一家以研发创新驱动的，集化学原料药、高端化学药及生物药研发、生产、销售于一体的高新技术企业，公司成立于2009年，并于2020年9月在上海证券交易所科创板挂牌上市（股票简称：苑东生物，股票代码：688513）。
